The Group's principal activity is to discover, develop and market small molecule drugs for the treatment of serious diseases. These drugs used for the treatment of diseases like HIV infection, chronic hepatitis C virus infection, inflammatory and autoimmune disorders, cancer, bacterial infection, pain and other neurological diseases, independently and with collaborators. The Group's telaprevir drug candidate, is an oral hepatitis C protease inhibitor and new class of antiviral treatments in clinical development that target hepatitis C virus or HCV, infection, a life-threatening disease.
Alacra Alerts:
Receive alerts on the latest reports on Vertex Pharmaceuticals Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
